Table 1

 Baseline characteristics for patients with extra-articular rheumatoid arthritis versus controls without extra-articular rheumatoid arthritis

ExRANon-ExRAp Value
CRP, C reactive protein; DMARDs, disease-modifying antirheumatic drugs; ExRA, extra-articular rheumatoid arthritis; HAQ, Health Assessment Questionnaire; IQR, interquartile range; TNF, tumour necrosis factor.
*Data available for 29 patients and 70 controls.
†Data available for 32 patients and 68 controls.
‡Infliximab, etanercept or adalimumab.
n3570
Sex
    Male1530
    Female2040
Age (years; mean (SD))65.5 (11.9)65.5 (11.6)
Duration (years; median (IQR))9.6 (2.3–19.4)8.6 (3.4–18.2)
Swollen joints (mean (SD))6.5 (5.7)3.0 (3.4)0.002
Ritchie index (mean (SD))9.5 (7.7)8.2 (7.6)0.41
HAQ* (mean (SD))1.19 (0.88)0.75 (0.74)0.01
CRP† (mg/l; median (IQR)39.5 (11.5–54.5)<9 (<9–15)<0.001
DMARDs, n (%)18 (51)57 (81)0.001
Methotrexate, n (%)8 (23)27 (39)0.11
TNF –inhibitors,‡ n (%)1 (3)7 (10)0.19
Glucocorticosteroids, n (%)13 (37)19 (27)0.29